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ABSTRACT
The incidence of melanoma is increasing worldwide,
and the prognosis for patients with high-risk or ad-
vanced metastatic melanoma remains poor despite ad-
vancesinthefield.Standardtreatmentforpatientswith
thick(>2.0mm)primarymelanomawithorwithoutre-
gional metastases to lymph nodes is surgery followed by
adjuvant therapy or clinical trial enrollment. Adjuvant
therapy with interferon- and cancer vaccines is dis-
cussed in detail. Patients who progress to stage IV met-
astatic melanoma have a median survival of <1 year.
Standard treatment with chemotherapy yields low re-
sponse rates, of which few are durable. Cytokine ther-
apy with IL-2 achieves durable benefits in a greater
fraction, but it is accompanied by severe toxicities that
requirethepatienttobehospitalizedforsupportduring
treatment. A systematic literature review of treatments
for advanced, metastatic disease was conducted to
presentthesuccessofcurrenttreatmentsandtheprom-
ise of those still in clinical development that may yield
incremental improvements in the treatment of ad-
vanced, metastatic melanoma. The Oncologist 2011;16:
5–24
INTRODUCTION
The incidence of melanoma is increasing worldwide, with a
growing fraction of patients with advanced disease for which
prognosis remains poor [1]. Treatment options are limited de-
spite advances in immunotherapy and targeted therapy. For
patientswithsurgicallyresected,thick(2mm)primarymel-
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only effective adjuvant therapy is interferon- (IFN-) [2].
However,becauseofthelimitedbenefitupondisease-freesur-
vival and the smaller potential improvement of overall sur-
vival [3, 4], the indication for IFN- treatment remains
controversial. Standard recommended therapy for patients
with stage IV metastasis according to the American Joint
Committee on Cancer (AJCC) is single-agent dacarbazine
(Bedford Laboratories, Bedford, Ohio), but responses to this
agentanditsoralanalogue,temozolomide(Merck&Co.Inc.,
Whitehouse Station, New Jersey), are 15% and generally
transient [5]. Among other treatment options, immunotherapy
withhigh-doseinterleukin(IL)-2achieveslong-term,durable,
complete responses in a small percentage of patients but has
neverbeenestablishedinaformal,phaseIII,randomizedcom-
parative study [6]. Biochemotherapy increases objective re-
sponse rates but has not been shown to significantly improve
survival compared with chemotherapy alone and is associated
with additive toxicity [7–10]. Clearly, new therapies are needed.
Adjuvant therapies for high-risk melanoma and therapies
for advanced, metastatic melanoma will be discussed. This
systematic literature review was performed to update a previ-
ous review of 41 randomized trials published through 2001
[11] and to identify new randomized trials that may serve to
change the paradigm of melanoma treatment in the future.
Thus, this review augments and provides a current analysis of
randomized trials in metastatic melanoma. Additionally, clin-
ical trial databases have been reviewed to identify and over-
view ongoing trials in melanoma worldwide.
METHODS
Search Strategy and Selection Criteria
Asystematicsearchstrategywasappliedasusedpreviously
[11]; this review updates previous analyses. The Medline
database was searched for articles published between Jan-
uary 1, 2002, and June 5, 2010. A combination of MeSH
headings was used: “melanoma, advanced”; “melanoma,
metastatic”; or “melanoma, disseminated” with the term
“randomized clinical trial” for trials in advanced disease
and “melanoma, adjuvant” or “melanoma, interferon” for
adjuvant IFN- trials for the trials conducted in the adju-
vant setting. Searches were limited to clinical trials and
publications in English, French, Italian, or German. The
“relatedarticles”featureofPubMedwasusedforallreports
that met the requested criteria as an additional means of
identifying potentially relevant investigations. The abstract
databases of the American Society of Clinical Oncology
(ASCO) and European Society for Medical Oncology an-
nual congresses were searched for further up-to-date clini-
cal trials. Textbook chapters and review articles were also
consulted. Additionally, in all reports, the list of references
was reviewed to find further relevant publications.
Statistical Analysis
Data derived from adjuvant trials with IFN- were ana-
lyzed using RevMan (The Cochrane Collaboration, http://
www.cc-ims.net/RevMan) software version 5.0. The
standardizedmeandifferencesand95%confidenceinterval
(CI) were computed and displayed graphically.
Adjuvant Therapy of Melanoma
Patients with thick (2.0 mm according to 2009 AJCC/
International Union Against Cancer [UICC] classification)
primarymelanomaandregionallymphnodemetastasesare
atincreasedriskofrecurrenceanddeath[12].Surgeryisthe
standard treatment [13, 14], and surgical excision margins
should be based on Breslow’s tumor thickness [15, 16].
Complete lymphadenectomy is recommended for patients
with involved regional nodes [13, 14]. Current recommen-
dations for patients with stage II (2.0 mm according to
AJCC/UICC classification, but negative nodes) melanoma
areforadjuvanttherapywithIFNorenrollmentinaclinical
trial[13,14].PatientswithstageIIImelanomatypicallyun-
dergo complete lymphadenectomy followed by adjuvant
therapywithIFNorenrollmentinaclinicaltrialofadjuvant
therapy [13, 14]. Over the past 25 years, adjuvant therapy
for immediate-risk (stage II and IIIA) and high-risk (stage
IIIBaswellasresectablestageIVM1a,M1b)patientshave
shifted from regional radiotherapy, systemic immunos-
timulants such as Bacillus Calmette-Guerin (BCG) and
Corynebacterium parvum, or pharmacologic immuno-
modulators such as levamisole, to recombinant DNA-pro-
duced biologic agents such as IFN-, granulocyte-
macrophage colony-stimulating factor, and antibodies that
have immunoregulatory function such as those that block
cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)
[17, 18].
IFN-
IFN-2b (Intron A, Merck & Co. Inc., Whitehouse Station,
New Jersey) was the first agent to show a significant sur-
vival benefit in patients with high-risk melanoma in a ran-
domized, controlled trial [19]. In the Eastern Cooperative
Oncology Group (ECOG) trial E1684, patients (N  287)
with high-risk resected cutaneous melanoma and regional
lymphnodemetastaseswererandomizedtostandardobser-
vation or to receive IFN-2b (20 million units [MIU]/m
2
per day) intravenously for 1 month and 10 MIU/m
2 subcu-
taneously 3 times per week for 48 weeks. Overall survival
was significantly prolonged with IFN-2b after a median
follow-up time of 6.9 years (median overall survival 3.82
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[95% CI  1.83–4.03] with observation only; p-value 
.0237) [19]. Subsequent to this first positive trial, a number
of studies have attempted to identify the optimal dose,
schedule,anddurationofIFN-foradjuvanttherapy(Figs.
1 and 2) [20–29]. In a follow-up trial comparing patients
(N  642) receiving high-dose IFN-2b (HDI) for 1 year,
low-dose IFN-2b (LDI) for 2 years, or observation, re-
lapse-free survival (RFS) was significantly enhanced with
HDI versus observation (p  .03), but overall survival was
not improved [21]. Although LDI was associated with a
greatly reduced incidence of grade 3/4 adverse events
(AEs) compared with HDI (1 [0.5%] vs. 17 [8.0%] grade 4
AEs, respectively) and the early RFS benefit was equiva-
lent to HDI after 3–4 years, LDI failed to achieve statisti-
cally significant improvement in RFS or durable impact on
relapseinthistrial.Itisnotablethatthistrialwasconducted
in part before and in part after the U.S. FDA approval of
HDI, and follow-up evaluation of patients assigned to ob-
servationinthetrialdemonstratedthat37patientshadbeen
treated at subsequent nodal relapse with HDI, offering an
explanationfortheabsenceofaneffectuponsurvivalinthis
experience. In a controlled trial of two lower doses of IFN
conducted in patients (N  1388) randomized to observa-
tionortotreatmentwithanintermediatedoseofIFN-2b(4
weeks with 10 MIU administered 5 times per week, fol-
lowed by 10 MIU 3 times per week for 1 year or 5 MIU 3
times per week for 2 years) for 13 or 25 months, intermedi-
ate-dose IFN-2b did not significantly improve distant me-
tastasis-free interval or overall survival outcomes [22].
Low-dose IFN-2b also failed to improve survival out-
comes versus observation alone when patients were ran-
domized to treatment with 3 MIU 2 times weekly for 6
months (N  95) or 3 MIU 3 times weekly for 2 years (N 
674) or 3 years (N  444) [23, 25, 29]. However, LDI did
improvedisease-freesurvivalcomparedversusobservation
alone when patients (N  311) received 3 MIU daily for 3
weeks and then 3 times weekly for 1 year (p  .02) and
when patients (N  499) were treated with 3 MIU 3 times
weekly for 18 months (p  .038) [24, 27].
The large number of clinical trials testing variations in
dosage, schedule, and duration of IFN- administration,
Figure 1. Forest plot of disease-free survival of patients with high-risk melanoma treated with various doses of IFN- adjuvant
therapy. Disease-free survival among patients with high-risk melanoma was improved with IFN- adjuvant therapy compared to
control (p  .0001; odds ratio  0.83; 95% CI  0.75–0.92). Treatment improved disease-free survival compared with control
regardless of dose or pegylation of the adjuvant IFN. Data analysis was performed using the program RevMan (The Cochrane
Collaboration).
Abbreviations: CI, confidence interval; IFN-, interferon-; N, total number of patients per group; n, number of patients with
disease progression.
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has prompted a number of attempts to consolidate and re-
view the available outcome data [3, 4, 30–32]. A meta-
analysis of the available published data from randomized
clinicaltrialswasreportedin2007,summarizingevent-free
survival and overall survival in patients with high-risk mel-
anoma treated with IFN- adjuvant therapy [32]. Clinical
data were sorted by IFN dose: high (20 MIU/m
2), interme-
diate (5–10 MIU/m
2), low (3 MIU/m
2), and very low (1
MIU/m
2) doses [32]. Groups were also stratified by dura-
tion of treatment (6 months, 12–18 months, or 24
months).Althoughtherewasastatisticallysignificantover-
all survival benefit for treatment of patients with IFN-
(p.008),thisassimilationdidnotfindevidenceofaclear
differenceinoverallsurvivalwithdifferentdoselevels(p
.8) or durations of treatment (p  .9) [32]. Thus, adjuvant
IFN improves overall survival of patients with stage II/III
melanoma, although the absolute benefit in terms of sur-
vival rate at 5 years was small (3%, 95% CI  1%–5%).
In this review, disease-free and overall survival of patients
treated with high-dose, intermediate-dose, low-dose, and
pegylated IFN (PEG–IFN) were compared (Figs. 1 and 2)
[19–27, 29, 33]. Similar to the meta-analysis by Wheatley
etal.[32],therewasaclearbenefitfordisease-freesurvival
(odds ratio [OR]  0.83; 95% CI  0.75–0.92) and overall
survival (OR  0.88; 95% CI  0.79–0.99) with adjuvant
therapy using IFN-, regardless of dose, schedule, dura-
tion, or formulation (pegylation).
Current trials are assessing the tolerability and efficacy
of more intense but shorter regimens of dosing with IFN-
2b [34] or PEG–IFN-2a and PEG–IFN-2b [35, 36]. A
fundamentalquestionhasbeenposedregardingwhetherthe
benefit of IFNs occurs through durable immunologic, anti-
angiogenic, or other antitumor mechanisms that would re-
quireprolonged,andperhapsindefinite,exposuretoIFN.A
recent phase III European Organization for Research and
Treatment of Cancer (EORTC) study (N  1256) showed
that prolonged treatment with PEG–IFN-2b (for up to 5
years) significantly improved recurrence-free survival
compared with observation in patients with resected stage
III melanoma (328 events compared with 368 events; haz-
ard ratio (HR)  0.82, 95% CI  0.71–0.96; p  .01) [33].
This effect is remarkably consistent with the aggregate as-
sessment of IFN effects on relapse in melanoma [3]. In the
EORTC trial, both gross nodal disease and microscopic
nodal disease were included, but the benefit of therapy ap-
Figure 2. Forest plot of overall survival in high risk patients treated with adjuvant interferon- (IFN-). Overall survival among
patients with high-risk melanoma was improved with IFN- adjuvant therapy compared to control (p  0.03; odds ratio  0.88;
95% CI  0.79–0.99). Treatment improved overall survival compared with control regardless of dose or pegylation of the adju-
vant IFN.
Abbreviations: CI, confidence interval; N, total number of patients per group; n, number of patients with disease progression.
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scopic metastatic disease [33]. The magnitude of this effect
appearstobelessthanthemagnitudeoftheHDIeffect,and
there is no hint of a survival benefit with this regimen
(HR0.99).ManypatientsinthePEG–IFN-2barm(191
of 627; 31%) discontinued therapy because of toxicities
[33]. The median duration of dosage, despite the initial
goals of this trial, was 12 months. A trial of the European
Association of Dermatologic Oncology investigated adju-
vant treatment efficacy of low-dose PEG–IFN-2b (100
g/wk) for 36 months in comparison to classic LDI for 18
months and did not find differences in disease-free or over-
all survival [37].
Otherstudieshaveinvestigatedthebenefitofderivative
components of the approved regimen of HDI, and specifi-
callythebenefitofintravenoushigh-doseinductiontherapy
alone. A randomized phase III trial by the Hellenic Coop-
erative Oncology Group tested a modified HDI regimen
versus a modified HDI induction regimen and showed that
1 month of modified intravenous IFN-2b induction was
not inferior to 1 year of modified HDI therapy [38]. The
currentU.S.intergrouptrialteststheIVHDIinductionreg-
imen versus observation. An early report on a study of
DeCOG has found that 1 month of HDI induction therapy
adds no benefit to LDI given for 2 years [39].
To date, the mechanism of the therapeutic effects of
IFN- is not completely known. A neoadjuvant trial with
HDI applied for 4 weeks before complete lymphadenec-
tomy in patients with macrometastatic lymph node metas-
tases and histologic comparison of pre- and post-treatment
specimens implicated an indirect immunomodulatory
mechanism [40]. In this trial, 20 patients who had bulky
nodal disease at presentation or recurrence were enrolled.
Remarkably, 55% of patients demonstrated objective clin-
ical response after only 20 doses of HDI, including 3 with a
complete response demonstrated pathologically. The ex-
amination of the nodal tumor tissue taken before and after
20 doses of IFN revealed increased infiltration of the tumor
tissue by dendritic cells (DCs) marked by CD11a; T cells
positive for CD3, CD4, and CD8; and striking ablation of
the STAT3 expression that is typically constitutively active
in melanoma. These findings argue that HDI has an immu-
nologic mechanism of action. Additional data from Yurk-
ovetsky et al. [41] revealed significant decreases of serum
levelsofimmunosuppressiveandtumorangiogenic/growth
stimulatory factors and increased levels of antiangiogenic
IFN- inducible protein 10 under IFN- treatment. This
study also demonstrates a profile of pro-inflammatory cy-
tokines that may serve to predict response to therapy.
Treatment benefits with IFN-, however, remain sub-
optimal, and the balance of this benefit weighed against the
toxicity and cost of therapy has led to differences in the
therapy pursued in different countries. In all western na-
tions, HDI has received regulatory approval for stage III
melanoma. In the United States, where three randomized
controlled trials have shown this regimen to be superior to
observation, as well as superior to LDI and a ganglioside
vaccine, most physicians offer this treatment to patients. In
Europe,LDIhasalsobeenapprovedforstageIImelanoma,
and this treatment is offered to patients. However, despite
regulatory approval, many countries (e.g., United King-
dom, Scandinavian countries, Australia, etc.) do not have
financial support for treatment with HDI and do not rou-
tinely offer HDI to patients.
Cancer Vaccines and Immunotherapies
Cancer vaccines have been pursued in hopes of enhancing
immune recognition and effector antitumor immune re-
sponses through improved antigen presentation and the
ability to elicit effector memory T-cell responses that are
durable[42].Increasedknowledgeoftherelevantantigenic
epitopes capable of eliciting antitumor immunity has
prompted a variety of vaccine approaches. Although vac-
cines are well tolerated, they rarely have been monitored
withmethodsthatarenowrecognizedtobecriticaltodetect
whether or not the vaccine induced an immune response.
Not surprisingly, the large phase III trials of older crude tu-
mor cell vaccines have not demonstrated robust clinical ev-
idenceofantitumoractivityeitherinadvanceddiseaseorin
the adjuvant setting [43]. A randomized, phase III study
(ECOG 1694) compared HDI with the ganglioside vaccine
GMK (ganglioside conjugate [GM2] coupled to keyhole
limpet hemocyanin and formulated with adjuvant QS-21
[ProgenicsPharmaceuticals,Tarrytown,NewYork])asad-
juvant therapies for patients with high-risk melanoma [44].
The GMK vaccination induces antibodies against GM2 ca-
pable of specifically binding GM2 and killing melanoma
cells in vitro through complement or antibody-dependent
cell-mediated cytotoxicity. Patients were documented to
have generated robust antibody immune responses to GM2
inthistrial,andthosewhohadimmunitytoGM2withthese
antibodies had a trend to an improved survival. However,
the study was terminated early when interim analyses dem-
onstrated a markedly inferior relapse-free and overall sur-
vival among patients who received GMK vaccine
compared with patients who received HDI [44]. Subse-
quent analyses comparing pre- and post-treatment patient
sera found that GMK had induced persistent (for at least 1
year) antibodies in 80% of vaccinated patients [45], so
these results were not explained by a lack of immune acti-
vation. In two other randomized, phase III trials, postoper-
ative adjuvant therapy with BCG alone or in combination
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cromet, Munich, Germany) tested as adjuvant treatment for
patients with resected stage III (n  1160) or stage IV (n 
496) melanoma was terminated because of the statistically
inferior relapse-free and overall survival of patients (stage
III)whoreceivedCanvaxinplusBCG,aswellasthefutility
oftheoriginalhypothesisthatCanvaxinwouldshowanim-
provement in relapse-free and overall survival [46]. The
fact that relapse-free and overall survival was shorter
among patients who received BCG plus vaccine suggests
that the vaccine may have induced tolerance to tumor anti-
gens rather than effector immunity. This question also
arises in the context of another large adjuvant vaccine trial
in patients with high-risk melanoma. The EORTC 18961
trial (N  1314) in patients with stage II melanoma com-
pared vaccination with a synthetic GM2 vaccine and obser-
vation. This trial was prematurely halted after the second
interim analysis (267 recurrences, median follow-up of 1.8
years) because, for the primary endpoint (RFS), the criteria
for stopping for futility were met. For distant metastasis-
free and overall survival, the results suggested no advanta-
geouseffectsofthevaccinecohort(143vs.152events,p
.36; 112 vs. 124 events, p  .25) [47].
Currently, a large phase III vaccine trial is ongoing in
patientswithstageIIIB/Cmelanomawhosetumorsexpress
MAGE-A3 antigen in lymph node metastases [48]. This
vaccine is conceptually quite different from the previously
described vaccines because it targets a cancer germline
family antigen that has been considerably better defined
thanthecrudeCanvaxinpreparation,anditinduceseffector
T-cell responses rather than antibody responses.
Peptide vaccines are another category of vaccine that
has been studied in large multicenter ECOG trials in the
United States. These studies in patients with advanced met-
astatic melanoma revealed the induction of immune re-
sponses; more than one-third of vaccinated patients had
increased T-cell production of IFN gamma as detected by
ELISPOT.Ofinterest,thosepatientswhodemonstratedim-
mune response to any of the three peptides studied (gp100,
MART-1/Melan-A, and tyrosinase HLA-A2 epitopes) had
significantly improved survival that was nearly double that
of patients who did not develop immunity to 1 or more of
the peptide vaccine epitopes. This triple vaccine has now
also been evaluated in the placebo-controlled E4697 inter-
group adjuvant trial (N  815), for which results are pend-
ing final evaluation [49].
In contrast to the various vaccines discussed above, an-
tibodies to immunoregulatory checkpoint molecules such
as CTLA-4 (for details, see below) have been shown to
elicit a broader stimulation of the immune system, with au-
toimmunetoxicitiesthatarereminiscentofIL-2[6](details
below), and the clinical and serologic evidence of autoim-
munity associated with IFN-2b [50]. An adjuvant therapy
with CTLA-4–blocking antibodies compared against pla-
cebo is presently being conducted by the EORTC, where-
asthe ECOG and U.S. Intergroup are conducting studies of
these antibodies compared with HDI [51].
Treatment of Metastatic Melanoma
Among patients with AJCC stage IV metastatic melanoma,
median survival time is estimated to be 8 months (2
months), and only 10% patients survive 5 years from
diagnosis of metastatic melanoma [12]. In the United
States, there are only two agents approved for treatment of
patients with metastatic melanoma: dacarbazine and high-
dose IL-2. Current consensus is that there is no single stan-
dard therapy for metastatic melanoma [13, 14], and single
agents are not likely to prove to be effective. Neither of the
FDA-approved systemic therapies has been ever been
shown to significantly prolong survival in phase III trials in
patients with advanced stage IV melanoma [14].
Chemotherapy
ChemotherapyisanacceptedpalliativetherapyforstageIV
metastatic disease (Table 1) [7, 9, 52–69], and dacarbazine
is the most widely used single chemotherapeutic agent for
the treatment of metastatic melanoma [70]. Dacarbazine
wasoriginallyreportedtoyieldobjectiveresponsesinupto
25% of patients in older phase II trials, but current trials in
more rigorous, large-scale, cooperative group settings have
shown response rates of 5%–12% [52, 54, 55]. Unfortu-
nately, most responses to this agent and its oral analogue
temozolomide are transient; only 1%–2% of patients
achieve a durable long-term response to chemotherapy
[11]. Temozolomide, an oral prodrug that yields the same
active intermediate (3-methyl-[triazen-1-yl]imidazole-4-
carboxamide) as dacarbazine, has been demonstrated to be
as effective as dacarbazine in phase III studies and is an
oral, although more expensive, alternative to dacarbazine
[71]. For symptomatic patients, or patients who are not el-
igible for current investigational trials, chemotherapy with
one of these agents remains a reasonable palliative option;
for novel agents being tested in clinical trials, chemother-
apy is an accepted comparator (Table 1) [9, 52–69]. Other
chemotherapies that have been explored include fotemus-
tine (Servier, Gidy, France), a chloroethyl nitrosourea that
has significantly improved the objective response rate
(15.2% vs. 6.8% in the intent-to-treat populations; p 
.043) and prolonged median overall survival, although not
significantly (7.3 vs. 5.6 months; p  .067), when com-
pared with dacarbazine in a phase III trial [52].
The antitumor activity of combinations of chemothera-
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agents (final data published)
Author Treatment schedule n
a CR (%) PR (%)
Response
p-value
Median
OS, mo
OS
p-value
Chemotherapy or multiple
agent therapy compared
with dacarbazine or
temozolomide as single
agent
Avril et al. 2004 52 Induction phase 112 2.7 12.5 7.3
Fotemustine: 100 mg/m
2 IV d 1,8,15; 5-wk rest period
Maintenance phase
Fotemustine: 100 mg/m
2 IV d1, q21d
vs. 0.043 0.067
Dacarbazine (DTIC): 250 mg/m
2 d1–5, q28d 117 0.9 6.0 5.6
Middleton et al. 2007
53
Histamine dihydrochloride: 1 mg bid SC d1–5 119 2.5 11.5 9.0
IL-2: 2.4 MIU/m
2 BID SC d1–5, 8–12, q28d
IFN-2b: 3 MIU SC daily
vs. NS 0.94
DTIC 850 mg/m
2 IV d1, q21d 122 2.5 10.1 7.7
Bedikian et al. 2006
54
Oblimersen: 7 mg/kg/d IV (continuous) d1–5 386 2.8 10.6 9.0
DTIC: 1,000 mg/m
2 IV d5, q21d
vs. 0.007 0.077
DTIC: 1,000 mg/m
2 IV d1, q21d 385 0.8 6.8 7.8
Schadendorf et al. 2006
55
Autologous peptide-loaded dendritic cell vaccination: SC d1,
q14d (first 5 cycles), thereafter q28d
53 0 3.8 9.3
vs. NS 0.48
DTIC: 850 mg/m
2 IV d1, q28d 55 0 5.5 11.6
Ranson et al. 2007 56 Lomeguatrib: 40/60/80 mg/d PO d1–5 52 1.9 11.5 7.6
Temozolomide: 125 mg/m
2/d PO d1–5, q28d
vs. NS NS
Temozolomide: 200 mg/m
2/d PO d1–5, q28d 52 3.8 13.4 7.7
Kaufmann et al. 2005
57
Temozolomide: 200 mg/m
2/d PO d1–5, q28d 137 8.0 16.1 9.7
IFN-2b: 5.0 MIU/m
2 SC 3/wk
vs. 0.036 0.16
Temozolomide: 200 mg/m
2/d PO d1–5, q28d 134 2.2 11.2 8.4
Bafaloukos et al 2005
58
Temozolomide: 200 mg/m
2/d PO d1–5, 65 10.8 18.5 12
Cisplatin: 75 mg/m
2 IV d1, q28d
vs. 0.695 0.9
Temozolomide: 200 mg/m
2/d PO d1–5, q28d 62 8.1 17.7 11.5
Danson et al. 2003 59 Temozolomide: 150 mg/m
2/d PO d1–5, 60 3.3 11.7 7.3
Thalidomide: 100 mg/d PO daily, q28d
vs. NS NS
Temozolomide: 200 mg/m
2/d PO d1–5, q28d 62 3.2 14.5 7.7
IFN-2b: 5.0 MIU/m
2 SC 3/wk
vs.
Temozolomide: 200 mg/m
2 PO every 8 h for 5 doses, q28d 55 0 9.1 5.3
McDermott et al. 2008
60
DTIC: 1,000 mg/m
2 d1, q21d 51 0 24 11.4
Sorafenib: 800 mg/d
vs. 0.194 0.93
DTIC: 1,000 mg/m
2, q21d 50 0 12 12.8
(continued)
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Author Treatment schedule n
a CR (%) PR (%)
Response
p-value
Median
OS, mo
OS
p-value
Biochemotherapy
compared with
polychemotherapy
Atkins et al. 2008 9 Cisplatin: 20 mg/m
2 IV d1–4 210 2.5 18.5 9.0
Vindesine: 1.2 mg/m
2 IV d1–4
DTIC: 800 mg/m
2 d1
IL-2: 9 	 10
6 IU/m
2/24-h IV
IFN-2b: 5 	 10
6 IU/m
2 SC d1–5, 8, 10, 12
GM-CSF: 5 g/kg SC d7–16
q21d
vs. 0.14 0.64
Cisplatin: 20 mg/m
2 IV d1–4 206 4.6 9.7 8.7
Vindesine: 1.2 mg/m
2 IV d1–4
DTIC: 800 mg/m
2 d1
q21d
Atzpodien et al. 2002
61
Cisplatin: 35 mg/m
2, d 1–3 60 13.3 16.6 12
Carmustine: 150 mg/m
2, d1, cycles1&3only
DTIC: 220 mg/m
2, d1–3
Tamoxifen: 20 mg/m
2, daily
IL-2: SC
10 	 10
6 IU/m
2, d3–5 wk 4
5 	 10
6 IU /m
2, d1,3,5 wk 5
IFN-:S C
5 	 10
6 IU/m
2,d 1w k4
5 	 10
6 IU/m
2 d1,3,5 wk 5
q35d
vs. NS 0.79
Cisplatin: 35 mg/m
2 IV, d1–3 64 11.9 23.4 13
Carmustine: 150 mg/m
2 IV, d1, cycles1&3
DTIC: 220 mg/m
2 IV, d1–3
Tamoxifen: 20 mg/m
2 IV, daily
q35d
Keilholz et al. 2005
62
DTIC: 250 mg/m
2 IV 183 3.3 17.5 9.0
Cisplatin: 30 mg/m
2 IV d1–3
IFN-2b: 10 	 10
6 IU/m
2 SC d1–5
IL-2:
18 	 10
6 IU/m
2/ 6hI Vd 5
18 	 10
6 IU/m
2/ 1 2hI Vd 6
18 	 10
6 IU/m
2/ 2 4hI Vd 7
4.5 	 10
6 IU/m
2/24 h IV d8–10
q28d
vs. 0.74 0.31
DTIC: 250 mg/m
2 IV 180 3.9 18.9 9.0
Cisplatin: 30 mg/m
2 IV d1–3
IFN--2b: 10 	 10
6 IU/m
2 SC d1–5
q28d
Bajetta et al. 2006 7 Cisplatin: 30 mg/m
2 IV d1–3 72 4.2 29.2 11
Vindesine: 2.5 mg/m
2 IV d1
DTIC: 250 mg/m
2 IV d1–3
IL-2: 9 	 10
6 IU SC d1–5, 8–15
IFN-2b: 5 	 10
6 IU/m
2 SC d1–5
q21d
vs. Not reported NS
Cisplatin: 30 mg/m
2 IV d1–3 72 0 20.8 12
Vindesine: 2.5 mg/m
2 IV d1
DTIC: 250 mg/m
2 d1–3
(continued)
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Author Treatment schedule n
a CR (%) PR (%)
Response
p-value
Median
OS, mo
OS
p-value
Further therapeutic
schedules
Punt et al. 2006 63 Cisplatin: 30 mg/m
2 IV d1–3 45 2.2 20 9.5
DTIC: 250 mg/m
2 IV d1–3
IFN-:1 0	 10
6 IU/m
2 SC d1–5
IL-2: IV
1 mg/m
2/6 h d4;
1 mg/m
2/12 h d5;
1 mg/m
2/24 h d6;
0.25 mg/m
2/24 h d7–9
q28d
vs. NS NS
DTIC: 850 mg/m
2 IV d1, q21d for 2 cycles followed by 44 4.5 11.4 10.5
Cisplatin: 30 mg/m
2 IV d1–3
DTIC: 250 mg/m
2 IV d1–3
IFN-:1 0	 10
6 IU/m
2 SC d1–5
IL-2: IV
1 mg/m
2/6 h d4;
1 mg/m
2/12 h d5;
1 mg/m
2/24 h d6,
0.25 mg/m
2/24 h d7–9
Richtig et al. 2004 64 Temozolomide: 150 mg/m
2 PO d1–5 20 5 30 14.5 for
the
whole
group
of
patients
IFN-2b: 10 	 10
6 IU/m
2 SC every other day d6–27
q28d
vs. 0.35 NS
Temozolomide: 150 mg/m
2 PO d1–5 27 14.8 7.4
IFN-2b: 10 	 10
6 IU flat dose SC every other day
d6–27
q28d
Glover et al. 2003 65 Cisplatin: 150 mg/m
2 SC 49 2 18.4 7.52
WR-2721: 910 mg/m
2
q21d
vs. NS NS
Cisplatin: 120 mg/m
2 IV q21d 45 0 15.6 7.58
Vuoristo et al. 2005
66
DTIC: 200 mg/m
2 IV d1–5 31 10 3 9.8
Vincristine: 1 mg/m
2 (max 2 mg) IV d1–4,
Bleomycin: 15 mg IV d2,5
CCNU: 80 mg PO d1
q28d
nIFN-:3	 10
6 IU SC/d8–50, following 6 	 10
6 IU 3/wk
vs. 0.82 0.62
DTIC: 200 mg/m
2 IV d1–5 25 12 12 7.5
Vincristine: 1 mg/m
2 (max. 2 mg) IV d1–4,
Bleomycin: 15 mg IV d2,5
CCNU: 80 mg PO d1
q28d
rIFN-2b: 3 	 10
6 IU SC/d8–50, following 6 	 10
6 IU 3/wk
vs.
(continued)
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Author Treatment schedule n
a CR (%) PR (%)
Response
p-value
Median
OS, mo
OS
p-value
DTIC: 250 mg/m2 IV d1–5, q28d 25 4 4 11.1
nIFN-:3	 10
6 IU SC/d8–50, following 6 	 10
6 IU 3/wk
vs.
DTIC: 250 mg/m
2 IV d1–5, q28d 25 4 8 9.1
rIFN-2b: 3 	 10
6 IU SC/d8–50, following 6 	 10
6 IU
3	/wk
Reichle et al. 2007 67 Trofosfamide: 50 mg orally 3 times daily 32 8.2
vs. 0.045
Trofosfamide: 50 mg orally 3 times daily 35 18.8
Rofecoxib: 25 mg orally d1
Pioglitazone: 60 mg orally d1
Hauschild et al. 2009
68
Paclitaxel: 225 mg/m
2 IV d1 135 0 15 10.5
Carboplatin AUC 6 IV d1 q21d
vs. 1.00 0.92
Paclitaxel: 225 mg/m
2 IV d1 135 0 16 10.5
Carboplatin AUC 6 IV d1
Sorafenib 400 mg PO 2 times daily q21d
Maio et al. 2010 69 DTIC 800 mg/m
2 IV d1 97 2 5 9.3
IFN-:3	 10
6 IU/m
2 SC d11–15
Thymosin-1 1.6 mg SC d8–11;15–18
q28d
vs.
DTIC 800 mg/m
2 IV d1 97 3 7 NS 8.6 0.08
IFN-:3	 10
6 IU/m
2 SC d11–15
Thymosin-1 3.2mg SC d8–11;15–18
q28d
vs.
DTIC 800 mg/m
2 IV d1 98 2 4 10.3
IFN-:3	 10
6 IU/m
2 SC d11–15
Thymosin-1 6.4mg SC d8–11,15–18
q28d
vs.
DTIC 800 mg/m
2 IV d1 99 2 10 9.3
Thymosin-1 3.2 mg d 8–11,15–18
q28d
vs.
DTIC 800 mg/m
2 IV d1 97 0 4 6.6
IFN-:3	 10
6 IU/m
2 SC d11–15
q28d
Hodi et al. 2010 87 Ipilimumab 3 mg/kg IV d1 403 0.2 5.5 0.04
b 10.0 0.001
gp100 peptide vaccine SC q21d
vs.
Ipilimumab 3 mg/kg IV d1 q21d 137 1.5 9.5 0.001
b 10.1 0.003
vs.
gp100 peptide vaccine SC q21d 136 0 1.5 6.4
aEvaluable patients.
bBest overall response rate.
Abbreviations: AUC, area under the concentration–time curve; bid, twice daily; CCNU, Lomustine; CR, complete response;
d, day; GM-CSF, granulocyte-macrophage colony stimulating factor; h, hour; IFN, interferon; IL, interleukin; IU,
international units; IV, intravenously; MIU, million international units; nIFN-, natural interferon alfa; NS, not shown; OS,
overall survival; PO, by mouth; PR, partial response; q, every; rIFN-2b, recombinant interferon alfa 2b; SC,
subcutaneously; wk, week.
14 Review of Medical Treatments in Melanomapeutic agents has been evaluated as a consequence of the
increasinglyfrequentlyheldbeliefthatsingleagentsareun-
likely to improve the outcome of patients with advanced
metastatic melanoma (Table 1 and Fig. 3) [7, 9, 52–69].
Other polychemotherapies tested in phase III trials (e.g.,
Dartmouth regimen: cisplatin/vinblastine/dacarbazine/
tamoxifen) have failed to demonstrate a survival benefit
compared with dacarbazine alone [9].
IL-2 and Other Immunotherapies
High-dose recombinant IL-2 (aldesleukin, Proleukin;
Prometheus Laboratories Inc., San Diego, California) re-
ceivedU.S.FDAapprovalforthetreatmentofpatientswith
metastaticmelanomain1998.Anobjectiveresponserateof
16% was observed in the collected set of phase II trials in
patients (N  47) with metastatic melanoma presented for
regulatory review. Single-agent therapy was administered
usingtheinpatienthigh-doseregimenof600,000U/kgIL-2
every8hoursforupto14doses[72].Asmallpercentageof
patients (5%) [73] experienced long-term, durable com-
plete responses with IL-2, which has been interpreted as a
potentialcure.However,thistherapyhasnotbeenshownto
improve overall survival in the patient population and has
never been evaluated in a phase III setting [74, 75]. In ad-
dition, IL-2 treatment-related toxicity is severe [72] and re-
quires inpatient intensive care [76, 77]. Common dose-
limiting toxicities include hemodynamic toxicity (e.g.,
hypotension, edema, weight gain, decreased renal func-
tion), respiratory insufficiency, and neurotoxicity [76, 77].
High-dose recombinant IL-2 treatment is the first immuno-
therapyofmetastaticmelanomathatinducesalowpercent-
age of long-term cancer remissions. Such long-term cancer
remissions have not been convincingly demonstrated after
chemotherapy. High-dose recombinant IL-2 has not been
approved in Europe and is offered only in specialized can-
cer centers in the United States.
Furthermore, a recent multicenter study (N  185) con-
ducted by Schwartzentruber and colleagues [78] has built
upon high-dose IL-2, evaluating the adding benefit of a
peptidevaccine(gp100:209–217[210M]).Theremarkable
finding that emerged from this trial was that peptide vacci-
nation added significantly to the benefit of high-dose IL-2,
improving response rates (22.1% vs. 9.7%, p  .02) and
prolonging progression-free survival (1.6 vs. 2.9 months,
p  .0101) significantly. Overall survival was also pro-
longed in the combination arm (17.6 vs. 12.8 months, p 
.09)butdidnotreachsignificance.Oneongoingstudy(N
387) will determine whether the combination of IL-2 and
vaccination with autologous melanoma cells can improve
antitumor responses and overall survival compared with
IL-2 alone (Table 2) [79]. Another vaccine currently under
investigation in phase III is a DNA/lipid complex (allovec-
tin) that enhances the expression of the major histocompat-
ibility complex protein HLA-B7 and induces a fraction of
antitumor responses (Table 2) [80].
An area of great research interest focuses on the role of
DCsthatarerecognizedasthenaturalsourceofantigenpre-
sentation.TheonlyrandomizedtrialofavaccineusingDCs
and melanoma peptides did not show any clinical benefit
compared with chemotherapy (dacarbazine) [55], but
Figure 3. Overall survival of patients treated with different therapies for melanoma. The data analyzed are listed in Table 1. On
this figure, the error bars represent the 95% confidence interval. Abbreviation: DTIC, dacarbazine.
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DCs are now available and will doubtless be evaluated in
the future (Table 1).
Biochemotherapy
Biochemotherapy (e.g., cisplatin, vinblastine, and dacarba-
zinecombinedwithIFN-IL-2)increasesresponserates
but has not been shown to significantly improve survival
compared with chemotherapy alone in randomized phase II
and III trials [7, 8, 63]. In a systematic review of 41 ran-
domized clinical trials of patients receiving various treat-
ment schedules, including biochemotherapy regimens,
none of them improved progression-free survival (PFS) or
overall survival (Fig. 3) [11]. Similarly, objective response
to polychemotherapy with cisplatin, carmustine, dacarba-
zine, and tamoxifen was also improved with the addition of
subcutaneous IL-2 and IFN- in a randomized study, but
this did not result in significantly improved PFS or overall
survival (Table 1) [61]. Furthermore, the addition of IL-2
does not significantly enhance the efficacy of dacarbazine/
IFN [81] or dacarbazine/cisplatin/IFN-2b (Table 1) [62].
Combinations with temozolomide have not been more suc-
cessfulthanthosewithdacarbazine.InaphaseIII,random-
ized study, the addition of IFN- to temozolomide
improved the objective response rate but not overall sur-
vival compared with temozolomide alone (Table 1) [57]. A
phase II study compared combinations of temozolomide
witheitherthalidomideorIFN-totreatmentwithtemozo-
lomide alone, but neither combination significantly im-
proved objective response rate or median overall survival
(Table1)[59].AnotherrandomizedphaseIIstudyanalyzed
the efficacy and tolerability of bleomycin, vincristine, lo-
mustine, and dacarbazine (BOLD) combined with natural
IFN- or recombinant IFN-2b (nIFN- or rIFN-2b, re-
spectively) [66]. Treatment groups included dacarbazine
plus nIFN-, BOLD plus nIFN-, dacarbazine plus rIFN-
2b, and BOLD plus rIFN-2b. There were no significant
differences in objective response rate or overall survival
among these four treatments.
Although a recent meta-analysis of 18 trials and nearly
2,500 patients with metastatic melanoma suggested a ben-
efit of biochemotherapy in terms of objective response, no
benefit in terms of overall survival was found (p  .9) [82].
A similar pattern was observed in a phase III ECOG-led in-
tergroup U.S. study comparing polychemotherapy treat-
ment with cisplatin, vinblastine, and dacarbazine (CVD,
n  195) alone or given in combination with IL-2 and IFN-
2b (BCT, n  200) administered as first-line treatment of
patients with metastatic melanoma [9]. The objective re-
sponse rate was slightly higher in the BCT arm than in the
CVD arm (19.5% vs. 13.8%, respectively; p  .140); me-
dian PFS was significantly longer in the BCT arm than in
the CVD arm (4.8 vs. 2.9 months; p  .015). However, the
addition of IL-2 and IFN-2b to chemotherapy was associ-
ated with greater toxicity and no improvements in overall
survival or durable responses; the BCT regimen cannot be
recommended for patients with metastatic melanoma [9].
AninterestingobservationhasbeenreportedbyO’Dayand
colleagues from a study with 133 metastasized melanoma
patients treated first line with a biochemotherapy induction
regimen including CVD, IL-2, IFN-, and granulocyte
macrophagecolony-stimulatingfactor(GM-CSF)[83].Pa-
tients not experiencing disease progression received main-
tenance biotherapy with low-dose IL-2 and GM-CSF
followedbyintermittentpulsesofdecrescendoIL-2over12
months. The median survival time in this trial was 13.5
months, and the 12- and 24-month survival rates were 57%
and23%,respectively.Ithasbeensuggestedthatthisprom-
ising regimen should be studied in a randomized clinical
trial.
Untiltoday,biochemotherapyhasnotdemonstratedsig-
nificantclinicalbenefitinadjuvanttrialsnorinrandomized
prospective studies in the metastatic setting, but it is asso-
ciated with additive toxicity. The addition of maintenance
biotherapy may be suitable to prolong overall survival.
Presently, biochemotherapy regimens cannot be regarded
asstandardclinicalpracticeandshouldbefurtherevaluated
in clinical trials.
Emerging Therapies for Patients with Metastatic
Melanoma
An increased understanding of tumor biology and the com-
plexity of immune antitumor response and immune regula-
tion has led to the development of novel agents. Several
approaches to overcoming tolerance that appear promising
in clinical trials include blockade of inhibitory immune re-
ceptors, inhibition of oncogenic kinase pathways, down-
regulation of antiapoptotic proteins, and adoptive cell
therapy after nonmyeloablative lymphodepletion (Table 2)
[79, 80, 84–92].
Antibody Blockade of Cytotoxic
T-Lymphocyte–Associated Antigen 4
Full T-cell activation requires stimulation through the T-
cell receptor as well as a costimulatory signal provided by
the binding of B7 on the antigen-presenting cell (e.g., den-
driticcell)toCD28ontheTcell.CytotoxicT-lymphocyte–
associated antigen 4 is a homologue of CD28 and is an
inhibitory T-cell receptor that is upregulated following T-
cell activation. The normal function of CTLA4 is to com-
pete with CD28 to bind B7 to downregulate T-cell
activation, acting as a natural “brake” by removing the co-
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Sponsor
Study and treatment
schedule Stage
a N
b Primary endpoint
Fully recruited, interim
data available
Pfizer 92 Tremelimumab vs. DTIC or
temozolomide
Stage IV or unresectable stage
IIIC with N3 status for
regional lymph nodes and
in-transit or satellite lesions
655 OS (not achieved)
EORTC 71 Temozolomide vs. DTIC Unresectable stage III or stage
IV
859 OS (not achieved)
Synta (Symmetry
trial) 123
c Elesclomol (STA-4783) and
paclitaxel vs. Paclitaxel
Stage IV 630 PFS (not achieved)
Genta (AGENDA
trial) 124
DTIC and oblimersen vs.
DTIC and placebo
Unresectable stage III or stage
IV (low-normal LDH, defined
as 0.8 times the upper limit of
normal)
300 PFS (not achieved) OS
ECOG/SWOG 105 Carboplatin and paclitaxel and
sorafenib vs. Carboplatin and
paclitaxel
Unresectable stage III or stage
IV
834 OS (not achieved)
Fully recruited, under
evaluation, no interim
data available
BMS/Medarex 84 DTIC and Ipilimumab vs.
DTIC and placebo
Unresectable stage III or stage
IV
500 PFS
ECOG/SWOG 105 Carboplatin and paclitaxel and
sorafenib vs. Carboplatin and
paclitaxel
Unresectable stage III or stage
IV
800 OS
Vical 80 Allovectin and DTIC vs.
DTIC
Unresectable stage III or stage
IV
280 Median TTP
Currently recruiting
GSK 48 GSK 2132231A vaccine vs.
placebo
MAGE-A3–positive, resected
stage III
1300 Disease-free survival
BMS 51 Ipilimumab vs. placebo High-risk resected stage III 950 Recurrence-free survival
Cambridge
University Hospitals
NHS Foundation
Trust 125
Bevacizumab vs. placebo Resected stage IIb–III 1320 OS
Hoffmann-La Roche
89
RG7204 vs. DTIC Unresectable stage III or stage
IV
896 OS
Eli Lilly and
Company 90
Tasisulam vs. Paclitaxel Stage IV 800 OS
Abraxis 91 ABI-007 vs. DTIC Stage IV 514 PFS
AVAX technologies
79
IL-2 and M-Vax vs. IL-2 and
placebo
Stage IV 387 Best overall antitumor
response OS (%) at 2
years
BioVex Limited
126
OncoVEXGM-CSF vs. GM-
CSF
Unresectable Stage IIIb, IIIc,
or IV
430 Durable response rate
aDisease stage by AJCC/UICC criteria.
bRequired, planned number of patients.
cThis study was halted for safety reasons by an independent Data Monitoring Committee; there was also an imbalance in the
outcome of patients treated in the different cohorts.
Abbreviations: AJCC, American Joint Committee on Cancer; DTIC, dacarbazine; EORTC, European Organization for
Research and Treatment of Cancer; IL, interleukin; LDH, lactate dehydrogenase; OS, overall survival; PFS, progression-
free survival; TTP, time to progression; UICC, International Union Against Cancer.
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blocked with an anti-CTLA4 monoclonal antibody (mAb),
which has a higher affinity for CTLA4 than B7. Thus, the
inhibitory signal is prevented and the “brake” on T-cell ac-
tivation is released. Two fully human anti-CTLA4 mAb’s
are currently in clinical development: tremelimumab (CP-
675,206; Pfizer Inc., New York) and ipilimumab (MDX-
010; Medarex, Inc./Bristol-Myers Squibb, New York).
Objective response rates of patients with metastatic mela-
noma treated with either of the two anti-CLTA4 mAb’s as
single agents are similar (7%–10%) [92–100] and resem-
ble the response rate found in patients treated with high-
doseIL-2.Responsestoanti-CTLA4mAb’saredurable(as
much as 70%) [87, 92] but may take as long as 12 weeks or
even longer to develop [98, 101], and late-onset objective
responses are sometimes preceded by months of stable dis-
ease or even transient disease progression [101]. Side ef-
fects with CTLA4 blockade are autoimmune-related but
less acute than those observed with exogenous cytokine
therapy and are manageable. Commonly reported AEs in-
clude diarrhea and rash [87, 92]. Several randomized stud-
ies are ongoing to assess whether these early observations
of durable responses will translate into an overall survival
benefit (Table 2) [84, 87, 92]. In a phase III randomized
study of tremelimumab (15 mg/kg administered once every
3 months, n  328) and chemotherapy (n  327) with
dacarbazine or temozolomide in treatment-naive patients,
median survival was longer (11.76 months) in patients
treated with tremelimumab compared with chemotherapy
(10.71 months) [92]. However, the difference was not sta-
tistically significant (HR chemotherapy/tremelimumab
1.04; p  .729), and the trial was halted at the second in-
terimanalysis.However,patientswithclinicalbenefitfrom
tremelimumabtreatmentarecontinuingonstudy,andmore
mature survival and response data are anticipated. Ipili-
mumab is also currently being investigated in a large phase
IIItrialinpatientswithmetastaticmelanoma(Table2)[84].
The results of a randomized phase III trial for single ipili-
mumab treatment versus gp100 vaccination and versus the
combination of ipilimumab and gp100 vaccination have
been recently published, showing improved overall sur-
vival of a median duration of 10.1 and 10.0 months in the
ipilimumab arm and the combined arm, respectively, in
comparison to 6.4 months in the vaccination alone arm. Al-
thoughobjectiveresponserateswereratherlowwith10.9%
in the ipilimumab alone arm and 5.7% in the combined ip-
ilimumab and vaccination arm versus 1.5% in the gp100
vaccination alone arm, highly significant differences in
hazard rates for overall survival resulted were detected be-
tween ipilimumab alone versus vaccination alone (0.66;
95%CI0.51–0.87;p.003)andbetweenthecombined
arm versus vaccination alone (0.68; 95% CI  0.55–0.85;
p  .001) [87]. This observation may result in approval of
ipilimumab by health authorities for the treatment of ad-
vanced melanoma.
Inhibitors of the Mitogen-Activated Protein
Kinase Pathway
The most frequently (60%–70%) mutated oncogene identi-
fiedtodateinmelanomaisBRAF,anupstreammediatorof
the mitogen-activated protein kinase (MAPK) pathway
[102]. Increased activation of the MAPK pathway is impli-
cated in melanoma tumorigenesis and is enhanced in ad-
vanced-stage melanoma [103]. Sorafenib (Nexavar, BAY
43–9006; Bayer HealthCare Pharmaceuticals Inc., Wayne,
New Jersey, and Onyx Pharmaceuticals, Inc., Emeryville,
California) is an oral multikinase BRAF inhibitor that has
been widely investigated. Unfortunately, the majority of
published clinical studies have failed to show any benefit
associated with the addition of sorafenib to standard che-
motherapy [60, 68, 104–106].
In contrast to nonselective multikinase inhibitors,
RG7204, formerly PLX4032 (Hoffmann-La Roche, Basel,
Switzerland/Plexxikon, Inc., Berkeley, California), is a
novel selective inhibitor of the oncogenic V600E mutant
BRAF kinase. A phase I dose-escalation study in patients
with solid tumors carrying the V600E mutation was re-
ported at ASCO 2009 and showed objective responses in
70% of patients treated with RG7204 [107]. At ASCO
2010, data from an international multicenter phase I study
were reported showing an objective fluorodeoxyglucose
positronemissiontomographyresponseinall22treatedpa-
tients. The best overall response was determined by con-
ventionalassessmentusingResponseEvaluationCriteriain
Solid Tumors (RECIST) criteria, and an objective response
rate of 86% has been described. No relationship was found
betweenreductionintargetlesions,maximumstandardized
uptake value (SUVmax) and response by RECIST, PFS,
and time to achieve RECIST partial response [108]. A con-
secutive phase III study comparing RG7204 versus dacar-
bazine is currently recruiting patients worldwide (Table 2)
[89]. Other BRAF inhibitors such as GSK2118436 (Glaxo-
SmithKline PLC, Brentford, U.K.) and RAF265 (Novartis,
Basel, Switzerland) are likewise in first clinical trials [109,
110].ForGSK2118436aclinicalobjectiveresponserateof
66% has recently been reported in V600 mutant melanoma
patients treated with 150 mg 2 times daily (b.i.d.) [111].
AZD6244 (ARRY-142886; AstraZeneca, Wilmington,
Delaware)isapotent,selectiveinhibitorofMEK1/2kinase
[112]. Its therapeutic target is downstream but in the same
signaling pathway as the kinase targeted by the BRAF in-
hibitors. First results of AZD6244 antitumor activity were
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ing partial responses in mainly BRAF-mutated patients.
AZD6244 is currently being tested in a phase II, multi-
center, open-label, randomized study comparing its antitu-
mor activity in combination with dacarbazine versus
dacarbazine alone for patients with stage III or IV malig-
nant melanoma [114]. First clinical results have also been
reported for the MEK inhibitor GSK1120212 in 20 patients
with BRAF mutant melanoma showing six partial re-
sponses and two complete responses (40% OR). Interest-
ingly, two partial responses have likewise been observed in
22 BRAF wild-type melanoma patients [115].
Tasisulam
Tasisulam (Eli Lilly and Company, Indianapolis) is a novel
antiproliferative and cytotoxic drug that induces apoptosis
through the mitochondrial cell death pathway. In addition
to the apoptotic activity, a loss of mitochondrial membrane
potential and the induction of reactive oxygen species ap-
pear to be the relevant anticancer mechanisms. Interim data
of a phase II trial showed an overall response rate of 12%
and disease stabilization in an additional 35% of patients
[116]. Recently, a phase III trial comparing tasisulam ver-
sus paclitaxel alone was initiated, recruiting 800 patients
worldwide [90].
ABI-007 (Abraxane)
ABI-007 (Abraxane, Abraxis BioScience Inc., Los Ange-
les) is an albumin-bound paclitaxel that is approved for the
treatment of metastatic breast cancer and is now being in-
vestigated in phase III compared with dacarbazine in previ-
ously untreated patients with advanced melanoma.
Abraxanehasimportanttolerancebenefitscomparedtosol-
vent-based paclitaxel, which has a high risk of Cremophor
EL-related hypersensitivity reactions [91].
Adoptive Cell Therapy
To date, adoptive cell therapy that has been developed by
Rosenberg and colleagues has yielded some of the most
dramatic responses among patients with metastatic mela-
noma. Objective response rates in highly selected patients
enrolled in this series have been stated to range between
49% and 72%. Adoptive cell therapy as undertaken by this
groupbasedattheNationalCancerInstituteiscomplexand
costly, involving multiple steps: first, specifically sensi-
tized antitumor lymphocytes must be isolated from the pa-
tient’s tumor or stimulated in vitro with autologous
melanoma cells. For this purpose, tumor-infiltrating lym-
phocytes are cultured in vitro. These are grown in IL-2, ex-
hibiting major histocompatibility complex–restricted
recognition of the autologous melanoma cells. Second, the
antitumorlymphocyteshavetobeexpandedinvitrotolarge
numbers. The efficacy of adoptive cell therapy depends on
thepresenceoflargenumbersofantitumorlymphocytesca-
pableofrecognizingthemelanomacellsanddestroyingthe
cancer cells in vivo. The ideal number for the adoptive
transfer is 10
11 cells. Objective clinical responses were
associated with cells that were cultured for shorter time pe-
riods, and a protocol for rapid expansion has therefore been
developed. The in vitro expansion was performed with use
of IL-2 and anti-CD3-antibodies in the presence of irradi-
ated allogeneic feeder cells. Cells were harvested 14 days
after in vitro expansion [117]. Third, lymphodepletion has
been performed as preparation of the host before adoptive
celltransfer.Sevendaysbeforeadoptivetransfer,anonmy-
eloablative lymphodepleting regimen consisting of cyclo-
phosphamide and fludarabine has been applied. It has been
suggested that this has to be supplemented by total body ir-
radiation in single fractions of 2 Gy or with 12 Gy admin-
istered as 2 Gy b.i.d. for 3 days. Fourth, the adoptive cell
transfer accompanied by a high-dose treatment with IL-2
for 3 days is performed. The tumor-infiltrating lympho-
cytes were applied as a bolus intravenous infusion over
0.5–1 hours, and the high-dose IL-2 treatment was started
within 24 hours. Patients who received total body irradia-
tion additionally received autologous purified cryopre-
servedCD34
hematopoieticstemcellsfromagranulocyte
colony-stimulating factor-mobilized pheresis [118]. After
nonmyeloablative but lymphodepleting chemotherapy,
adoptivecelltransfertherapy(N35)resultedinobjective
responseratesof51%[119].Byintensifyingthelymphode-
pleting therapy (N  25) through the addition of total body
irradiation with a total dose of 12 Gy, the response rate
could be increased to 72% [118].
It is important to mention that this therapeutic approach
isingeneralnotavailableformetastaticmelanomapatients.
First, this particular therapeutic approach has exclusively
been established at the surgery branch, National Cancer In-
stitute in Bethesda, Maryland. There are very few groups
worldwide that developed therapeutic approaches with
lymphodepletion and adoptive cell transfer [120–122].
Second,thisprocedureisverycomplexandhasseveralcrit-
ical steps, such as the isolation of the tumor-infiltrating
lymphocytes and their in vitro expansion, which is labor-
intensiveaswellascostly.Third,theselectedpatientsmust
have an excellent performance status with no other severe
concomitant disease. Therefore, only a few patients per
year have been included in phase II studies, and to date, no
phase III study has been initiated. Nevertheless, tumor re-
missions accomplished by such a strategy seem to be dura-
ble and may result in cancer cure.
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Despite decades of clinical research, patients with ad-
vanced melanoma continue to have a poor prognosis, and
no agents have shown statistically significant improvement
in overall survival in a phase III trial in patients with meta-
static melanoma. For high-risk, resected disease, adjuvant
therapywithIFN-hasbeenshowntoconsistentlyincrease
relapse-free survival, as well as overall survival in some
studies. Standard off-protocol treatment for patients with
metastatic melanoma is evolving, and where mutations can
be documented in BRAF (V600E) or the c-Kit gene, there
exist promising new approaches to targeted therapy that
have altered the paradigm of systemic therapy. Apart from
these, or for patients who are symptomatic and unable to
consider the pursuit of new investigational trials, chemo-
therapyofferstransient,palliativeefficacy.Advancesinthe
understanding of the mechanism of chemotherapy resis-
tance offer the hope for improved results with chemother-
apy, and the triumvirate of more effective chemotherapy,
immunotherapy, and targeted therapy are likely to be com-
bined with one another for significant advances in mela-
noma over the coming few years. Because of the potential
benefits of new targeted drugs and of immunotherapies,
treatment guidelines for melanoma recommend the inclu-
sion of patients with metastatic melanoma in clinical trials.
Several new immunotherapies have demonstrated
promising antitumor activity with manageable side effects
in patients with advanced melanoma. These include the an-
ti-CTLA4 mAb’s tremelimumab and ipilimumab, and the
targeted agents RG7204 (BRAF V600E), AZD6244
(BRAF V600E), and the novel proapoptotic agent tasisu-
lam. Although early clinical trials have not indicated that
any of these offers a “breakthrough” in terms of antitumor
activity for all patients, each will likely offer incremental
improvements over standard care. Complex immunothera-
pies with adoptive T-cell transfer after nonmyeloablative
lymphodepletion suggest response rates that are extraordi-
nary, but we must remember that these results are derived
from highly selected patient samples, without large multi-
center phase III trials to date. Ongoing clinical trials will
hopefullyelucidatethetherapeuticmechanismsoftheseap-
proaches and provide survival benefit to patients with mel-
anoma.
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